nodes	percent_of_prediction	percent_of_DWPC	metapath
Enzalutamide—AR—hematologic cancer	0.187	0.599	CbGaD
Enzalutamide—ALB—hematologic cancer	0.064	0.205	CbGaD
Enzalutamide—ABCB1—hematologic cancer	0.0611	0.196	CbGaD
Enzalutamide—CYP2B6—Thiotepa—hematologic cancer	0.0175	0.0367	CbGbCtD
Enzalutamide—CYP2C9—Bexarotene—hematologic cancer	0.0112	0.0234	CbGbCtD
Enzalutamide—ABCB1—Lenalidomide—hematologic cancer	0.0108	0.0227	CbGbCtD
Enzalutamide—CYP2B6—Ifosfamide—hematologic cancer	0.00994	0.0208	CbGbCtD
Enzalutamide—CYP2C8—Bortezomib—hematologic cancer	0.00981	0.0205	CbGbCtD
Enzalutamide—CYP3A5—Daunorubicin—hematologic cancer	0.00976	0.0204	CbGbCtD
Enzalutamide—CYP2D6—Lomustine—hematologic cancer	0.00949	0.0199	CbGbCtD
Enzalutamide—ALB—Imatinib—hematologic cancer	0.0093	0.0195	CbGbCtD
Enzalutamide—CYP2C9—Idarubicin—hematologic cancer	0.00925	0.0194	CbGbCtD
Enzalutamide—CYP3A5—Thalidomide—hematologic cancer	0.00889	0.0186	CbGbCtD
Enzalutamide—CYP2B6—Nilotinib—hematologic cancer	0.00863	0.0181	CbGbCtD
Enzalutamide—CYP3A5—Teniposide—hematologic cancer	0.00848	0.0178	CbGbCtD
Enzalutamide—CYP2D6—Idarubicin—hematologic cancer	0.00846	0.0177	CbGbCtD
Enzalutamide—CYP2C19—Bortezomib—hematologic cancer	0.00823	0.0172	CbGbCtD
Enzalutamide—CYP3A5—Ifosfamide—hematologic cancer	0.00783	0.0164	CbGbCtD
Enzalutamide—CYP2C8—Ifosfamide—hematologic cancer	0.00753	0.0158	CbGbCtD
Enzalutamide—CYP3A5—Imatinib—hematologic cancer	0.00748	0.0157	CbGbCtD
Enzalutamide—CYP2D6—Hydroxyurea—hematologic cancer	0.00719	0.0151	CbGbCtD
Enzalutamide—CYP2C19—Thalidomide—hematologic cancer	0.00717	0.015	CbGbCtD
Enzalutamide—CYP2C9—Bortezomib—hematologic cancer	0.00684	0.0143	CbGbCtD
Enzalutamide—CYP2C19—Teniposide—hematologic cancer	0.00684	0.0143	CbGbCtD
Enzalutamide—CYP2C8—Nilotinib—hematologic cancer	0.00653	0.0137	CbGbCtD
Enzalutamide—CYP3A4—Bexarotene—hematologic cancer	0.00649	0.0136	CbGbCtD
Enzalutamide—ABCB1—Daunorubicin—hematologic cancer	0.00635	0.0133	CbGbCtD
Enzalutamide—CYP2C19—Ifosfamide—hematologic cancer	0.00631	0.0132	CbGbCtD
Enzalutamide—CYP2D6—Bortezomib—hematologic cancer	0.00626	0.0131	CbGbCtD
Enzalutamide—ABCB1—Alitretinoin—hematologic cancer	0.00622	0.013	CbGbCtD
Enzalutamide—ALB—Prednisone—hematologic cancer	0.00613	0.0128	CbGbCtD
Enzalutamide—CYP3A4—Lomustine—hematologic cancer	0.00604	0.0126	CbGbCtD
Enzalutamide—CYP3A4—Busulfan—hematologic cancer	0.00604	0.0126	CbGbCtD
Enzalutamide—CYP2C19—Imatinib—hematologic cancer	0.00603	0.0126	CbGbCtD
Enzalutamide—CYP3A5—Dasatinib—hematologic cancer	0.00601	0.0126	CbGbCtD
Enzalutamide—CYP2C9—Thalidomide—hematologic cancer	0.00596	0.0125	CbGbCtD
Enzalutamide—CYP2B6—Irinotecan—hematologic cancer	0.00593	0.0124	CbGbCtD
Enzalutamide—ALB—Irinotecan—hematologic cancer	0.00581	0.0122	CbGbCtD
Enzalutamide—CYP2C9—Teniposide—hematologic cancer	0.00569	0.0119	CbGbCtD
Enzalutamide—CYP3A4—Thiotepa—hematologic cancer	0.00538	0.0113	CbGbCtD
Enzalutamide—CYP2C9—Ifosfamide—hematologic cancer	0.00525	0.011	CbGbCtD
Enzalutamide—CYP2C9—Imatinib—hematologic cancer	0.00501	0.0105	CbGbCtD
Enzalutamide—ABCB1—Imatinib—hematologic cancer	0.00487	0.0102	CbGbCtD
Enzalutamide—CYP2B6—Cisplatin—hematologic cancer	0.00483	0.0101	CbGbCtD
Enzalutamide—CYP3A5—Irinotecan—hematologic cancer	0.00467	0.00978	CbGbCtD
Enzalutamide—CYP2D6—Imatinib—hematologic cancer	0.00459	0.0096	CbGbCtD
Enzalutamide—CYP2C9—Nilotinib—hematologic cancer	0.00456	0.00954	CbGbCtD
Enzalutamide—ABCB1—Nilotinib—hematologic cancer	0.00442	0.00926	CbGbCtD
Enzalutamide—ABCB1—Vinorelbine—hematologic cancer	0.00439	0.00918	CbGbCtD
Enzalutamide—CYP3A4—Methoxsalen—hematologic cancer	0.00418	0.00876	CbGbCtD
Enzalutamide—CYP2D6—Nilotinib—hematologic cancer	0.00417	0.00873	CbGbCtD
Enzalutamide—CYP2D6—Vinorelbine—hematologic cancer	0.00413	0.00865	CbGbCtD
Enzalutamide—CYP3A5—Vincristine—hematologic cancer	0.00408	0.00855	CbGbCtD
Enzalutamide—CYP3A4—Bortezomib—hematologic cancer	0.00398	0.00833	CbGbCtD
Enzalutamide—CYP2C19—Prednisone—hematologic cancer	0.00397	0.00832	CbGbCtD
Enzalutamide—ABCB1—Dasatinib—hematologic cancer	0.00391	0.00818	CbGbCtD
Enzalutamide—CYP2B6—Dexamethasone—hematologic cancer	0.0039	0.00818	CbGbCtD
Enzalutamide—ABCB1—Mitoxantrone—hematologic cancer	0.00386	0.00808	CbGbCtD
Enzalutamide—CYP3A4—Daunorubicin—hematologic cancer	0.00381	0.00797	CbGbCtD
Enzalutamide—CYP3A5—Etoposide—hematologic cancer	0.00374	0.00783	CbGbCtD
Enzalutamide—CYP2C8—Etoposide—hematologic cancer	0.0036	0.00753	CbGbCtD
Enzalutamide—ABCB1—Betamethasone—hematologic cancer	0.00344	0.00721	CbGbCtD
Enzalutamide—ABCB1—Gemcitabine—hematologic cancer	0.00341	0.00714	CbGbCtD
Enzalutamide—ABCB1—Prednisolone—hematologic cancer	0.0034	0.00711	CbGbCtD
Enzalutamide—CYP3A4—Cytarabine—hematologic cancer	0.00336	0.00703	CbGbCtD
Enzalutamide—CYP3A4—Teniposide—hematologic cancer	0.00331	0.00693	CbGbCtD
Enzalutamide—CYP2B6—Doxorubicin—hematologic cancer	0.00324	0.00678	CbGbCtD
Enzalutamide—ABCB1—Prednisone—hematologic cancer	0.00321	0.00671	CbGbCtD
Enzalutamide—CYP3A5—Dexamethasone—hematologic cancer	0.00308	0.00644	CbGbCtD
Enzalutamide—ALB—Methotrexate—hematologic cancer	0.00308	0.00644	CbGbCtD
Enzalutamide—CYP3A4—Ifosfamide—hematologic cancer	0.00305	0.00639	CbGbCtD
Enzalutamide—ABCB1—Irinotecan—hematologic cancer	0.00304	0.00636	CbGbCtD
Enzalutamide—CYP2C8—Dexamethasone—hematologic cancer	0.00296	0.00619	CbGbCtD
Enzalutamide—CYP3A4—Imatinib—hematologic cancer	0.00292	0.00611	CbGbCtD
Enzalutamide—CYP3A4—Ruxolitinib—hematologic cancer	0.00275	0.00575	CbGbCtD
Enzalutamide—ABCB1—Vinblastine—hematologic cancer	0.0027	0.00566	CbGbCtD
Enzalutamide—ABCB1—Vincristine—hematologic cancer	0.00266	0.00556	CbGbCtD
Enzalutamide—CYP3A4—Nilotinib—hematologic cancer	0.00265	0.00555	CbGbCtD
Enzalutamide—CYP3A4—Vinorelbine—hematologic cancer	0.00263	0.0055	CbGbCtD
Enzalutamide—CYP2C9—Cisplatin—hematologic cancer	0.00255	0.00535	CbGbCtD
Enzalutamide—CYP2D6—Vinblastine—hematologic cancer	0.00255	0.00533	CbGbCtD
Enzalutamide—CYP2C19—Dexamethasone—hematologic cancer	0.00248	0.00519	CbGbCtD
Enzalutamide—ABCB1—Cisplatin—hematologic cancer	0.00248	0.00519	CbGbCtD
Enzalutamide—ABCB1—Etoposide—hematologic cancer	0.00243	0.0051	CbGbCtD
Enzalutamide—CYP3A4—Triamcinolone—hematologic cancer	0.0024	0.00503	CbGbCtD
Enzalutamide—CYP3A4—Dasatinib—hematologic cancer	0.00234	0.0049	CbGbCtD
Enzalutamide—CYP3A4—Mitoxantrone—hematologic cancer	0.00231	0.00484	CbGbCtD
Enzalutamide—CYP2C9—Dexamethasone—hematologic cancer	0.00206	0.00432	CbGbCtD
Enzalutamide—CYP3A4—Betamethasone—hematologic cancer	0.00206	0.00432	CbGbCtD
Enzalutamide—CYP3A4—Prednisolone—hematologic cancer	0.00203	0.00426	CbGbCtD
Enzalutamide—ABCB1—Dexamethasone—hematologic cancer	0.002	0.00419	CbGbCtD
Enzalutamide—CYP3A4—Prednisone—hematologic cancer	0.00192	0.00402	CbGbCtD
Enzalutamide—CYP2D6—Dexamethasone—hematologic cancer	0.00189	0.00395	CbGbCtD
Enzalutamide—CYP3A4—Irinotecan—hematologic cancer	0.00182	0.00381	CbGbCtD
Enzalutamide—ABCB1—Doxorubicin—hematologic cancer	0.00166	0.00348	CbGbCtD
Enzalutamide—CYP3A4—Vinblastine—hematologic cancer	0.00162	0.00339	CbGbCtD
Enzalutamide—ABCB1—Methotrexate—hematologic cancer	0.00161	0.00337	CbGbCtD
Enzalutamide—Bicalutamide—AR—hematologic cancer	0.00161	0.608	CrCbGaD
Enzalutamide—CYP3A4—Vincristine—hematologic cancer	0.00159	0.00333	CbGbCtD
Enzalutamide—CYP2D6—Doxorubicin—hematologic cancer	0.00156	0.00328	CbGbCtD
Enzalutamide—CYP3A4—Etoposide—hematologic cancer	0.00146	0.00305	CbGbCtD
Enzalutamide—CYP3A4—Dexamethasone—hematologic cancer	0.0012	0.00251	CbGbCtD
Enzalutamide—Nilutamide—AR—hematologic cancer	0.00104	0.392	CrCbGaD
Enzalutamide—CYP3A4—Doxorubicin—hematologic cancer	0.000995	0.00208	CbGbCtD
Enzalutamide—AR—hematopoietic system—hematologic cancer	0.000421	0.0566	CbGeAlD
Enzalutamide—CYP2C19—hematopoietic system—hematologic cancer	0.00039	0.0525	CbGeAlD
Enzalutamide—CYP2C8—hematopoietic system—hematologic cancer	0.00034	0.0458	CbGeAlD
Enzalutamide—AR—gonad—hematologic cancer	0.00032	0.0431	CbGeAlD
Enzalutamide—CYP3A5—hematopoietic system—hematologic cancer	0.000307	0.0413	CbGeAlD
Enzalutamide—CYP2B6—hematopoietic system—hematologic cancer	0.000305	0.0411	CbGeAlD
Enzalutamide—CYP2C9—hematopoietic system—hematologic cancer	0.000302	0.0407	CbGeAlD
Enzalutamide—AR—blood—hematologic cancer	0.000279	0.0375	CbGeAlD
Enzalutamide—ALB—testis—hematologic cancer	0.000265	0.0357	CbGeAlD
Enzalutamide—CYP2C19—blood—hematologic cancer	0.000258	0.0348	CbGeAlD
Enzalutamide—AR—lung—hematologic cancer	0.000244	0.0329	CbGeAlD
Enzalutamide—CYP2B6—gonad—hematologic cancer	0.000232	0.0312	CbGeAlD
Enzalutamide—AR—testis—hematologic cancer	0.000231	0.031	CbGeAlD
Enzalutamide—CYP3A4—hematopoietic system—hematologic cancer	0.000231	0.031	CbGeAlD
Enzalutamide—CYP2D6—hematopoietic system—hematologic cancer	0.000227	0.0305	CbGeAlD
Enzalutamide—CYP2C8—blood—hematologic cancer	0.000226	0.0303	CbGeAlD
Enzalutamide—CYP3A5—blood—hematologic cancer	0.000204	0.0274	CbGeAlD
Enzalutamide—CYP2B6—blood—hematologic cancer	0.000202	0.0272	CbGeAlD
Enzalutamide—CYP2C9—blood—hematologic cancer	0.0002	0.027	CbGeAlD
Enzalutamide—ALB—lymph node—hematologic cancer	0.000192	0.0259	CbGeAlD
Enzalutamide—CYP2C8—testis—hematologic cancer	0.000187	0.0251	CbGeAlD
Enzalutamide—CYP3A5—lung—hematologic cancer	0.000178	0.024	CbGeAlD
Enzalutamide—CYP2B6—lung—hematologic cancer	0.000177	0.0239	CbGeAlD
Enzalutamide—CYP2B6—testis—hematologic cancer	0.000167	0.0225	CbGeAlD
Enzalutamide—AR—lymph node—hematologic cancer	0.000167	0.0225	CbGeAlD
Enzalutamide—ABCB1—hematopoietic system—hematologic cancer	0.000163	0.022	CbGeAlD
Enzalutamide—CYP3A4—blood—hematologic cancer	0.000153	0.0206	CbGeAlD
Enzalutamide—CYP2D6—blood—hematologic cancer	0.00015	0.0202	CbGeAlD
Enzalutamide—CYP2D6—testis—hematologic cancer	0.000124	0.0167	CbGeAlD
Enzalutamide—ABCB1—gonad—hematologic cancer	0.000124	0.0167	CbGeAlD
Enzalutamide—ABCB1—blood—hematologic cancer	0.000108	0.0145	CbGeAlD
Enzalutamide—ABCB1—bone marrow—hematologic cancer	0.000105	0.0141	CbGeAlD
Enzalutamide—ABCB1—lung—hematologic cancer	9.48e-05	0.0128	CbGeAlD
Enzalutamide—ABCB1—testis—hematologic cancer	8.94e-05	0.012	CbGeAlD
Enzalutamide—ABCB1—lymph node—hematologic cancer	6.48e-05	0.00872	CbGeAlD
Enzalutamide—Fatigue—Gemcitabine—hematologic cancer	5.38e-05	0.000357	CcSEcCtD
Enzalutamide—Muscular weakness—Epirubicin—hematologic cancer	5.36e-05	0.000356	CcSEcCtD
Enzalutamide—Headache—Hydroxyurea—hematologic cancer	5.34e-05	0.000355	CcSEcCtD
Enzalutamide—Asthenia—Thiotepa—hematologic cancer	5.32e-05	0.000353	CcSEcCtD
Enzalutamide—Vertigo—Triamcinolone—hematologic cancer	5.32e-05	0.000353	CcSEcCtD
Enzalutamide—Diarrhoea—Vinorelbine—hematologic cancer	5.31e-05	0.000353	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Cisplatin—hematologic cancer	5.3e-05	0.000352	CcSEcCtD
Enzalutamide—Infection—Etoposide—hematologic cancer	5.29e-05	0.000351	CcSEcCtD
Enzalutamide—Connective tissue disorder—Prednisone—hematologic cancer	5.28e-05	0.000351	CcSEcCtD
Enzalutamide—Dizziness—Bortezomib—hematologic cancer	5.26e-05	0.000349	CcSEcCtD
Enzalutamide—Neutropenia—Methotrexate—hematologic cancer	5.25e-05	0.000348	CcSEcCtD
Enzalutamide—Pruritus—Thiotepa—hematologic cancer	5.25e-05	0.000348	CcSEcCtD
Enzalutamide—Paraesthesia—Cisplatin—hematologic cancer	5.22e-05	0.000347	CcSEcCtD
Enzalutamide—Thrombocytopenia—Etoposide—hematologic cancer	5.21e-05	0.000346	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Methotrexate—hematologic cancer	5.21e-05	0.000346	CcSEcCtD
Enzalutamide—Skin disorder—Etoposide—hematologic cancer	5.17e-05	0.000344	CcSEcCtD
Enzalutamide—Dry skin—Doxorubicin—hematologic cancer	5.15e-05	0.000342	CcSEcCtD
Enzalutamide—Asthenia—Thalidomide—hematologic cancer	5.15e-05	0.000342	CcSEcCtD
Enzalutamide—Dizziness—Vinorelbine—hematologic cancer	5.13e-05	0.000341	CcSEcCtD
Enzalutamide—Convulsion—Triamcinolone—hematologic cancer	5.13e-05	0.000341	CcSEcCtD
Enzalutamide—Hypertension—Triamcinolone—hematologic cancer	5.11e-05	0.000339	CcSEcCtD
Enzalutamide—Pruritus—Thalidomide—hematologic cancer	5.07e-05	0.000337	CcSEcCtD
Enzalutamide—Diarrhoea—Thiotepa—hematologic cancer	5.07e-05	0.000337	CcSEcCtD
Enzalutamide—Bronchitis—Epirubicin—hematologic cancer	5.05e-05	0.000335	CcSEcCtD
Enzalutamide—Pneumonia—Methotrexate—hematologic cancer	5.03e-05	0.000334	CcSEcCtD
Enzalutamide—Nasopharyngitis—Doxorubicin—hematologic cancer	5.03e-05	0.000334	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Cisplatin—hematologic cancer	5.02e-05	0.000333	CcSEcCtD
Enzalutamide—Infestation NOS—Methotrexate—hematologic cancer	5e-05	0.000332	CcSEcCtD
Enzalutamide—Infestation—Methotrexate—hematologic cancer	5e-05	0.000332	CcSEcCtD
Enzalutamide—Headache—Bortezomib—hematologic cancer	4.98e-05	0.000331	CcSEcCtD
Enzalutamide—Muscular weakness—Doxorubicin—hematologic cancer	4.96e-05	0.000329	CcSEcCtD
Enzalutamide—Asthenia—Carmustine—hematologic cancer	4.94e-05	0.000328	CcSEcCtD
Enzalutamide—Neutropenia—Epirubicin—hematologic cancer	4.91e-05	0.000326	CcSEcCtD
Enzalutamide—Diarrhoea—Thalidomide—hematologic cancer	4.91e-05	0.000326	CcSEcCtD
Enzalutamide—Dizziness—Thiotepa—hematologic cancer	4.9e-05	0.000326	CcSEcCtD
Enzalutamide—Asthenia—Alitretinoin—hematologic cancer	4.9e-05	0.000325	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Epirubicin—hematologic cancer	4.88e-05	0.000324	CcSEcCtD
Enzalutamide—Angiopathy—Prednisone—hematologic cancer	4.87e-05	0.000324	CcSEcCtD
Enzalutamide—Headache—Vinorelbine—hematologic cancer	4.86e-05	0.000323	CcSEcCtD
Enzalutamide—Pollakiuria—Epirubicin—hematologic cancer	4.85e-05	0.000322	CcSEcCtD
Enzalutamide—Asthenia—Ifosfamide—hematologic cancer	4.84e-05	0.000321	CcSEcCtD
Enzalutamide—Pruritus—Alitretinoin—hematologic cancer	4.83e-05	0.000321	CcSEcCtD
Enzalutamide—Vertigo—Betamethasone—hematologic cancer	4.83e-05	0.000321	CcSEcCtD
Enzalutamide—Vertigo—Dexamethasone—hematologic cancer	4.83e-05	0.000321	CcSEcCtD
Enzalutamide—Infection—Triamcinolone—hematologic cancer	4.8e-05	0.000319	CcSEcCtD
Enzalutamide—Paraesthesia—Etoposide—hematologic cancer	4.78e-05	0.000318	CcSEcCtD
Enzalutamide—Pruritus—Ifosfamide—hematologic cancer	4.77e-05	0.000317	CcSEcCtD
Enzalutamide—Haematuria—Methotrexate—hematologic cancer	4.77e-05	0.000317	CcSEcCtD
Enzalutamide—Insomnia—Prednisolone—hematologic cancer	4.75e-05	0.000316	CcSEcCtD
Enzalutamide—Dizziness—Thalidomide—hematologic cancer	4.74e-05	0.000315	CcSEcCtD
Enzalutamide—Epistaxis—Methotrexate—hematologic cancer	4.72e-05	0.000313	CcSEcCtD
Enzalutamide—Asthenia—Vincristine—hematologic cancer	4.72e-05	0.000313	CcSEcCtD
Enzalutamide—Paraesthesia—Prednisolone—hematologic cancer	4.72e-05	0.000313	CcSEcCtD
Enzalutamide—Diarrhoea—Carmustine—hematologic cancer	4.71e-05	0.000313	CcSEcCtD
Enzalutamide—Pneumonia—Epirubicin—hematologic cancer	4.71e-05	0.000313	CcSEcCtD
Enzalutamide—Mental disorder—Prednisone—hematologic cancer	4.71e-05	0.000313	CcSEcCtD
Enzalutamide—Infestation—Epirubicin—hematologic cancer	4.68e-05	0.000311	CcSEcCtD
Enzalutamide—Infestation NOS—Epirubicin—hematologic cancer	4.68e-05	0.000311	CcSEcCtD
Enzalutamide—Bronchitis—Doxorubicin—hematologic cancer	4.67e-05	0.00031	CcSEcCtD
Enzalutamide—Diarrhoea—Alitretinoin—hematologic cancer	4.67e-05	0.00031	CcSEcCtD
Enzalutamide—Convulsion—Betamethasone—hematologic cancer	4.65e-05	0.000309	CcSEcCtD
Enzalutamide—Convulsion—Dexamethasone—hematologic cancer	4.65e-05	0.000309	CcSEcCtD
Enzalutamide—Headache—Thiotepa—hematologic cancer	4.64e-05	0.000309	CcSEcCtD
Enzalutamide—Hypertension—Dexamethasone—hematologic cancer	4.64e-05	0.000308	CcSEcCtD
Enzalutamide—Hypertension—Betamethasone—hematologic cancer	4.64e-05	0.000308	CcSEcCtD
Enzalutamide—Diarrhoea—Ifosfamide—hematologic cancer	4.61e-05	0.000306	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Etoposide—hematologic cancer	4.6e-05	0.000305	CcSEcCtD
Enzalutamide—Asthenia—Irinotecan—hematologic cancer	4.59e-05	0.000305	CcSEcCtD
Enzalutamide—Asthenia—Mitoxantrone—hematologic cancer	4.59e-05	0.000305	CcSEcCtD
Enzalutamide—Fatigue—Etoposide—hematologic cancer	4.59e-05	0.000305	CcSEcCtD
Enzalutamide—Anxiety—Betamethasone—hematologic cancer	4.56e-05	0.000303	CcSEcCtD
Enzalutamide—Anxiety—Dexamethasone—hematologic cancer	4.56e-05	0.000303	CcSEcCtD
Enzalutamide—Dizziness—Carmustine—hematologic cancer	4.55e-05	0.000303	CcSEcCtD
Enzalutamide—Neutropenia—Doxorubicin—hematologic cancer	4.54e-05	0.000302	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Doxorubicin—hematologic cancer	4.51e-05	0.0003	CcSEcCtD
Enzalutamide—Dizziness—Alitretinoin—hematologic cancer	4.51e-05	0.0003	CcSEcCtD
Enzalutamide—Diarrhoea—Vincristine—hematologic cancer	4.5e-05	0.000299	CcSEcCtD
Enzalutamide—Headache—Thalidomide—hematologic cancer	4.49e-05	0.000298	CcSEcCtD
Enzalutamide—Pollakiuria—Doxorubicin—hematologic cancer	4.49e-05	0.000298	CcSEcCtD
Enzalutamide—Asthenia—Gemcitabine—hematologic cancer	4.48e-05	0.000297	CcSEcCtD
Enzalutamide—Haematuria—Epirubicin—hematologic cancer	4.46e-05	0.000296	CcSEcCtD
Enzalutamide—Dizziness—Ifosfamide—hematologic cancer	4.46e-05	0.000296	CcSEcCtD
Enzalutamide—Pharyngitis—Methotrexate—hematologic cancer	4.46e-05	0.000296	CcSEcCtD
Enzalutamide—Urinary tract disorder—Methotrexate—hematologic cancer	4.43e-05	0.000295	CcSEcCtD
Enzalutamide—Epistaxis—Epirubicin—hematologic cancer	4.42e-05	0.000293	CcSEcCtD
Enzalutamide—Pruritus—Gemcitabine—hematologic cancer	4.41e-05	0.000293	CcSEcCtD
Enzalutamide—Urethral disorder—Methotrexate—hematologic cancer	4.4e-05	0.000292	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	4.4e-05	0.000292	CcSEcCtD
Enzalutamide—Sinusitis—Epirubicin—hematologic cancer	4.39e-05	0.000292	CcSEcCtD
Enzalutamide—Diarrhoea—Irinotecan—hematologic cancer	4.38e-05	0.000291	CcSEcCtD
Enzalutamide—Diarrhoea—Mitoxantrone—hematologic cancer	4.38e-05	0.000291	CcSEcCtD
Enzalutamide—Insomnia—Triamcinolone—hematologic cancer	4.37e-05	0.00029	CcSEcCtD
Enzalutamide—Pneumonia—Doxorubicin—hematologic cancer	4.36e-05	0.000289	CcSEcCtD
Enzalutamide—Infection—Dexamethasone—hematologic cancer	4.35e-05	0.000289	CcSEcCtD
Enzalutamide—Infection—Betamethasone—hematologic cancer	4.35e-05	0.000289	CcSEcCtD
Enzalutamide—Dizziness—Vincristine—hematologic cancer	4.35e-05	0.000289	CcSEcCtD
Enzalutamide—Paraesthesia—Triamcinolone—hematologic cancer	4.34e-05	0.000288	CcSEcCtD
Enzalutamide—Infestation NOS—Doxorubicin—hematologic cancer	4.33e-05	0.000288	CcSEcCtD
Enzalutamide—Infestation—Doxorubicin—hematologic cancer	4.33e-05	0.000288	CcSEcCtD
Enzalutamide—Headache—Carmustine—hematologic cancer	4.31e-05	0.000287	CcSEcCtD
Enzalutamide—Nervous system disorder—Dexamethasone—hematologic cancer	4.3e-05	0.000286	CcSEcCtD
Enzalutamide—Nervous system disorder—Betamethasone—hematologic cancer	4.3e-05	0.000286	CcSEcCtD
Enzalutamide—Thrombocytopenia—Betamethasone—hematologic cancer	4.29e-05	0.000285	CcSEcCtD
Enzalutamide—Thrombocytopenia—Dexamethasone—hematologic cancer	4.29e-05	0.000285	CcSEcCtD
Enzalutamide—Headache—Alitretinoin—hematologic cancer	4.27e-05	0.000284	CcSEcCtD
Enzalutamide—Diarrhoea—Gemcitabine—hematologic cancer	4.27e-05	0.000283	CcSEcCtD
Enzalutamide—Dizziness—Irinotecan—hematologic cancer	4.23e-05	0.000281	CcSEcCtD
Enzalutamide—Rhinitis—Epirubicin—hematologic cancer	4.21e-05	0.00028	CcSEcCtD
Enzalutamide—Vertigo—Prednisone—hematologic cancer	4.2e-05	0.000279	CcSEcCtD
Enzalutamide—Hypoaesthesia—Epirubicin—hematologic cancer	4.18e-05	0.000278	CcSEcCtD
Enzalutamide—Asthenia—Cisplatin—hematologic cancer	4.17e-05	0.000277	CcSEcCtD
Enzalutamide—Pharyngitis—Epirubicin—hematologic cancer	4.17e-05	0.000277	CcSEcCtD
Enzalutamide—Fatigue—Triamcinolone—hematologic cancer	4.16e-05	0.000277	CcSEcCtD
Enzalutamide—Urinary tract disorder—Epirubicin—hematologic cancer	4.15e-05	0.000276	CcSEcCtD
Enzalutamide—Oedema peripheral—Epirubicin—hematologic cancer	4.14e-05	0.000275	CcSEcCtD
Enzalutamide—Haematuria—Doxorubicin—hematologic cancer	4.13e-05	0.000274	CcSEcCtD
Enzalutamide—Connective tissue disorder—Epirubicin—hematologic cancer	4.13e-05	0.000274	CcSEcCtD
Enzalutamide—Urethral disorder—Epirubicin—hematologic cancer	4.12e-05	0.000274	CcSEcCtD
Enzalutamide—Headache—Vincristine—hematologic cancer	4.12e-05	0.000274	CcSEcCtD
Enzalutamide—Epistaxis—Doxorubicin—hematologic cancer	4.09e-05	0.000271	CcSEcCtD
Enzalutamide—Angiopathy—Methotrexate—hematologic cancer	4.07e-05	0.000271	CcSEcCtD
Enzalutamide—Sinusitis—Doxorubicin—hematologic cancer	4.06e-05	0.00027	CcSEcCtD
Enzalutamide—Convulsion—Prednisone—hematologic cancer	4.05e-05	0.000269	CcSEcCtD
Enzalutamide—Hypertension—Prednisone—hematologic cancer	4.04e-05	0.000268	CcSEcCtD
Enzalutamide—Headache—Mitoxantrone—hematologic cancer	4.01e-05	0.000266	CcSEcCtD
Enzalutamide—Headache—Irinotecan—hematologic cancer	4.01e-05	0.000266	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	3.99e-05	0.000265	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Betamethasone—hematologic cancer	3.99e-05	0.000265	CcSEcCtD
Enzalutamide—Arthralgia—Prednisone—hematologic cancer	3.98e-05	0.000265	CcSEcCtD
Enzalutamide—Diarrhoea—Cisplatin—hematologic cancer	3.98e-05	0.000264	CcSEcCtD
Enzalutamide—Anxiety—Prednisone—hematologic cancer	3.97e-05	0.000264	CcSEcCtD
Enzalutamide—Insomnia—Dexamethasone—hematologic cancer	3.96e-05	0.000263	CcSEcCtD
Enzalutamide—Insomnia—Betamethasone—hematologic cancer	3.96e-05	0.000263	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	3.95e-05	0.000263	CcSEcCtD
Enzalutamide—Paraesthesia—Dexamethasone—hematologic cancer	3.94e-05	0.000261	CcSEcCtD
Enzalutamide—Paraesthesia—Betamethasone—hematologic cancer	3.94e-05	0.000261	CcSEcCtD
Enzalutamide—Mental disorder—Methotrexate—hematologic cancer	3.93e-05	0.000261	CcSEcCtD
Enzalutamide—Headache—Gemcitabine—hematologic cancer	3.91e-05	0.00026	CcSEcCtD
Enzalutamide—Rhinitis—Doxorubicin—hematologic cancer	3.9e-05	0.000259	CcSEcCtD
Enzalutamide—Hypoaesthesia—Doxorubicin—hematologic cancer	3.87e-05	0.000257	CcSEcCtD
Enzalutamide—Pharyngitis—Doxorubicin—hematologic cancer	3.86e-05	0.000256	CcSEcCtD
Enzalutamide—Urinary tract disorder—Doxorubicin—hematologic cancer	3.84e-05	0.000255	CcSEcCtD
Enzalutamide—Oedema peripheral—Doxorubicin—hematologic cancer	3.83e-05	0.000254	CcSEcCtD
Enzalutamide—Asthenia—Etoposide—hematologic cancer	3.82e-05	0.000254	CcSEcCtD
Enzalutamide—Connective tissue disorder—Doxorubicin—hematologic cancer	3.82e-05	0.000254	CcSEcCtD
Enzalutamide—Angiopathy—Epirubicin—hematologic cancer	3.81e-05	0.000253	CcSEcCtD
Enzalutamide—Urethral disorder—Doxorubicin—hematologic cancer	3.81e-05	0.000253	CcSEcCtD
Enzalutamide—Infection—Prednisone—hematologic cancer	3.79e-05	0.000252	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.78e-05	0.000251	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.78e-05	0.000251	CcSEcCtD
Enzalutamide—Back pain—Methotrexate—hematologic cancer	3.78e-05	0.000251	CcSEcCtD
Enzalutamide—Fatigue—Betamethasone—hematologic cancer	3.78e-05	0.000251	CcSEcCtD
Enzalutamide—Fatigue—Dexamethasone—hematologic cancer	3.78e-05	0.000251	CcSEcCtD
Enzalutamide—Pruritus—Etoposide—hematologic cancer	3.77e-05	0.00025	CcSEcCtD
Enzalutamide—Nervous system disorder—Prednisone—hematologic cancer	3.74e-05	0.000249	CcSEcCtD
Enzalutamide—Skin disorder—Prednisone—hematologic cancer	3.71e-05	0.000246	CcSEcCtD
Enzalutamide—Mental disorder—Epirubicin—hematologic cancer	3.68e-05	0.000245	CcSEcCtD
Enzalutamide—Diarrhoea—Etoposide—hematologic cancer	3.64e-05	0.000242	CcSEcCtD
Enzalutamide—Back pain—Epirubicin—hematologic cancer	3.54e-05	0.000235	CcSEcCtD
Enzalutamide—Angiopathy—Doxorubicin—hematologic cancer	3.53e-05	0.000234	CcSEcCtD
Enzalutamide—Dizziness—Etoposide—hematologic cancer	3.52e-05	0.000234	CcSEcCtD
Enzalutamide—Vertigo—Methotrexate—hematologic cancer	3.51e-05	0.000233	CcSEcCtD
Enzalutamide—Leukopenia—Methotrexate—hematologic cancer	3.5e-05	0.000232	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.48e-05	0.000231	CcSEcCtD
Enzalutamide—Dizziness—Prednisolone—hematologic cancer	3.47e-05	0.000231	CcSEcCtD
Enzalutamide—Asthenia—Triamcinolone—hematologic cancer	3.47e-05	0.00023	CcSEcCtD
Enzalutamide—Insomnia—Prednisone—hematologic cancer	3.45e-05	0.000229	CcSEcCtD
Enzalutamide—Paraesthesia—Prednisone—hematologic cancer	3.43e-05	0.000228	CcSEcCtD
Enzalutamide—Pruritus—Triamcinolone—hematologic cancer	3.42e-05	0.000227	CcSEcCtD
Enzalutamide—Mental disorder—Doxorubicin—hematologic cancer	3.41e-05	0.000226	CcSEcCtD
Enzalutamide—Convulsion—Methotrexate—hematologic cancer	3.39e-05	0.000225	CcSEcCtD
Enzalutamide—Headache—Etoposide—hematologic cancer	3.34e-05	0.000222	CcSEcCtD
Enzalutamide—Arthralgia—Methotrexate—hematologic cancer	3.33e-05	0.000221	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.3e-05	0.00022	CcSEcCtD
Enzalutamide—Fatigue—Prednisone—hematologic cancer	3.29e-05	0.000219	CcSEcCtD
Enzalutamide—Headache—Prednisolone—hematologic cancer	3.29e-05	0.000219	CcSEcCtD
Enzalutamide—Vertigo—Epirubicin—hematologic cancer	3.29e-05	0.000218	CcSEcCtD
Enzalutamide—Leukopenia—Epirubicin—hematologic cancer	3.27e-05	0.000218	CcSEcCtD
Enzalutamide—Back pain—Doxorubicin—hematologic cancer	3.27e-05	0.000217	CcSEcCtD
Enzalutamide—Dizziness—Triamcinolone—hematologic cancer	3.19e-05	0.000212	CcSEcCtD
Enzalutamide—Convulsion—Epirubicin—hematologic cancer	3.17e-05	0.000211	CcSEcCtD
Enzalutamide—Infection—Methotrexate—hematologic cancer	3.17e-05	0.000211	CcSEcCtD
Enzalutamide—Hypertension—Epirubicin—hematologic cancer	3.16e-05	0.00021	CcSEcCtD
Enzalutamide—Asthenia—Betamethasone—hematologic cancer	3.14e-05	0.000209	CcSEcCtD
Enzalutamide—Asthenia—Dexamethasone—hematologic cancer	3.14e-05	0.000209	CcSEcCtD
Enzalutamide—Nervous system disorder—Methotrexate—hematologic cancer	3.13e-05	0.000208	CcSEcCtD
Enzalutamide—Thrombocytopenia—Methotrexate—hematologic cancer	3.12e-05	0.000207	CcSEcCtD
Enzalutamide—Arthralgia—Epirubicin—hematologic cancer	3.11e-05	0.000207	CcSEcCtD
Enzalutamide—Anxiety—Epirubicin—hematologic cancer	3.1e-05	0.000206	CcSEcCtD
Enzalutamide—Pruritus—Betamethasone—hematologic cancer	3.1e-05	0.000206	CcSEcCtD
Enzalutamide—Pruritus—Dexamethasone—hematologic cancer	3.1e-05	0.000206	CcSEcCtD
Enzalutamide—Skin disorder—Methotrexate—hematologic cancer	3.1e-05	0.000206	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.09e-05	0.000205	CcSEcCtD
Enzalutamide—Vertigo—Doxorubicin—hematologic cancer	3.04e-05	0.000202	CcSEcCtD
Enzalutamide—Leukopenia—Doxorubicin—hematologic cancer	3.03e-05	0.000201	CcSEcCtD
Enzalutamide—Headache—Triamcinolone—hematologic cancer	3.03e-05	0.000201	CcSEcCtD
Enzalutamide—Diarrhoea—Dexamethasone—hematologic cancer	3e-05	0.000199	CcSEcCtD
Enzalutamide—Diarrhoea—Betamethasone—hematologic cancer	3e-05	0.000199	CcSEcCtD
Enzalutamide—Infection—Epirubicin—hematologic cancer	2.97e-05	0.000197	CcSEcCtD
Enzalutamide—Convulsion—Doxorubicin—hematologic cancer	2.93e-05	0.000195	CcSEcCtD
Enzalutamide—Nervous system disorder—Epirubicin—hematologic cancer	2.93e-05	0.000194	CcSEcCtD
Enzalutamide—Thrombocytopenia—Epirubicin—hematologic cancer	2.92e-05	0.000194	CcSEcCtD
Enzalutamide—Hypertension—Doxorubicin—hematologic cancer	2.92e-05	0.000194	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.91e-05	0.000193	CcSEcCtD
Enzalutamide—Skin disorder—Epirubicin—hematologic cancer	2.9e-05	0.000193	CcSEcCtD
Enzalutamide—Dizziness—Betamethasone—hematologic cancer	2.9e-05	0.000193	CcSEcCtD
Enzalutamide—Dizziness—Dexamethasone—hematologic cancer	2.9e-05	0.000193	CcSEcCtD
Enzalutamide—Insomnia—Methotrexate—hematologic cancer	2.89e-05	0.000192	CcSEcCtD
Enzalutamide—Arthralgia—Doxorubicin—hematologic cancer	2.88e-05	0.000191	CcSEcCtD
Enzalutamide—Anxiety—Doxorubicin—hematologic cancer	2.87e-05	0.000191	CcSEcCtD
Enzalutamide—Paraesthesia—Methotrexate—hematologic cancer	2.86e-05	0.00019	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.86e-05	0.00019	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.75e-05	0.000183	CcSEcCtD
Enzalutamide—Fatigue—Methotrexate—hematologic cancer	2.75e-05	0.000183	CcSEcCtD
Enzalutamide—Headache—Betamethasone—hematologic cancer	2.75e-05	0.000182	CcSEcCtD
Enzalutamide—Headache—Dexamethasone—hematologic cancer	2.75e-05	0.000182	CcSEcCtD
Enzalutamide—Infection—Doxorubicin—hematologic cancer	2.74e-05	0.000182	CcSEcCtD
Enzalutamide—Asthenia—Prednisone—hematologic cancer	2.74e-05	0.000182	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.72e-05	0.000181	CcSEcCtD
Enzalutamide—Nervous system disorder—Doxorubicin—hematologic cancer	2.71e-05	0.00018	CcSEcCtD
Enzalutamide—Thrombocytopenia—Doxorubicin—hematologic cancer	2.7e-05	0.00018	CcSEcCtD
Enzalutamide—Pruritus—Prednisone—hematologic cancer	2.7e-05	0.000179	CcSEcCtD
Enzalutamide—Insomnia—Epirubicin—hematologic cancer	2.7e-05	0.000179	CcSEcCtD
Enzalutamide—Skin disorder—Doxorubicin—hematologic cancer	2.68e-05	0.000178	CcSEcCtD
Enzalutamide—Paraesthesia—Epirubicin—hematologic cancer	2.68e-05	0.000178	CcSEcCtD
Enzalutamide—Diarrhoea—Prednisone—hematologic cancer	2.61e-05	0.000173	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.58e-05	0.000171	CcSEcCtD
Enzalutamide—Fatigue—Epirubicin—hematologic cancer	2.57e-05	0.000171	CcSEcCtD
Enzalutamide—Dizziness—Prednisone—hematologic cancer	2.52e-05	0.000168	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.52e-05	0.000167	CcSEcCtD
Enzalutamide—Insomnia—Doxorubicin—hematologic cancer	2.5e-05	0.000166	CcSEcCtD
Enzalutamide—Paraesthesia—Doxorubicin—hematologic cancer	2.48e-05	0.000165	CcSEcCtD
Enzalutamide—Headache—Prednisone—hematologic cancer	2.39e-05	0.000159	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.38e-05	0.000158	CcSEcCtD
Enzalutamide—Fatigue—Doxorubicin—hematologic cancer	2.38e-05	0.000158	CcSEcCtD
Enzalutamide—Asthenia—Methotrexate—hematologic cancer	2.29e-05	0.000152	CcSEcCtD
Enzalutamide—Pruritus—Methotrexate—hematologic cancer	2.26e-05	0.00015	CcSEcCtD
Enzalutamide—Diarrhoea—Methotrexate—hematologic cancer	2.18e-05	0.000145	CcSEcCtD
Enzalutamide—Asthenia—Epirubicin—hematologic cancer	2.14e-05	0.000142	CcSEcCtD
Enzalutamide—Pruritus—Epirubicin—hematologic cancer	2.11e-05	0.00014	CcSEcCtD
Enzalutamide—Dizziness—Methotrexate—hematologic cancer	2.11e-05	0.00014	CcSEcCtD
Enzalutamide—Diarrhoea—Epirubicin—hematologic cancer	2.04e-05	0.000136	CcSEcCtD
Enzalutamide—Headache—Methotrexate—hematologic cancer	2e-05	0.000133	CcSEcCtD
Enzalutamide—Asthenia—Doxorubicin—hematologic cancer	1.98e-05	0.000132	CcSEcCtD
Enzalutamide—Dizziness—Epirubicin—hematologic cancer	1.97e-05	0.000131	CcSEcCtD
Enzalutamide—Pruritus—Doxorubicin—hematologic cancer	1.95e-05	0.00013	CcSEcCtD
Enzalutamide—Diarrhoea—Doxorubicin—hematologic cancer	1.89e-05	0.000126	CcSEcCtD
Enzalutamide—Headache—Epirubicin—hematologic cancer	1.87e-05	0.000124	CcSEcCtD
Enzalutamide—Dizziness—Doxorubicin—hematologic cancer	1.83e-05	0.000121	CcSEcCtD
Enzalutamide—Headache—Doxorubicin—hematologic cancer	1.73e-05	0.000115	CcSEcCtD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	4.24e-06	8.48e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—NUP214—hematologic cancer	4.24e-06	8.48e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—ADCY7—hematologic cancer	4.23e-06	8.46e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—NCOA3—hematologic cancer	4.23e-06	8.46e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	4.23e-06	8.46e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	4.22e-06	8.43e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—FHL2—hematologic cancer	4.21e-06	8.43e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—NUP214—hematologic cancer	4.2e-06	8.4e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—SDC1—hematologic cancer	4.2e-06	8.39e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—GSTT1—hematologic cancer	4.19e-06	8.38e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	4.16e-06	8.32e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—ABCG2—hematologic cancer	4.15e-06	8.3e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—MTR—hematologic cancer	4.15e-06	8.3e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—AGRN—hematologic cancer	4.13e-06	8.26e-05	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	4.13e-06	8.26e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—MTR—hematologic cancer	4.12e-06	8.23e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—ABCG2—hematologic cancer	4.12e-06	8.23e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—SDC1—hematologic cancer	4.1e-06	8.19e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—ENO2—hematologic cancer	4.07e-06	8.14e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	4.07e-06	8.14e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—ENO2—hematologic cancer	4.04e-06	8.07e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	4.01e-06	8.02e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CD44—hematologic cancer	4e-06	8e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—NQO1—hematologic cancer	4e-06	8e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CD44—hematologic cancer	3.97e-06	7.95e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—NQO1—hematologic cancer	3.97e-06	7.95e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.96e-06	7.92e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—GSTT1—hematologic cancer	3.95e-06	7.9e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—GSTP1—hematologic cancer	3.94e-06	7.88e-05	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—IL2—hematologic cancer	3.93e-06	7.85e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	3.92e-06	7.85e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—HMMR—hematologic cancer	3.92e-06	7.83e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—IDH2—hematologic cancer	3.92e-06	7.83e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—GSTT1—hematologic cancer	3.91e-06	7.83e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.91e-06	7.83e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.89e-06	7.79e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—SDC1—hematologic cancer	3.86e-06	7.72e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.85e-06	7.71e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—GSTP1—hematologic cancer	3.85e-06	7.7e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—SDC1—hematologic cancer	3.83e-06	7.65e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.78e-06	7.57e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CYCS—hematologic cancer	3.78e-06	7.57e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CYCS—hematologic cancer	3.76e-06	7.52e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—HSP90AA1—hematologic cancer	3.76e-06	7.52e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—HSP90AA1—hematologic cancer	3.74e-06	7.48e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—ABCB1—hematologic cancer	3.73e-06	7.46e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ARNTL—hematologic cancer	3.68e-06	7.36e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	3.67e-06	7.35e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.65e-06	7.31e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—ABCB1—hematologic cancer	3.64e-06	7.29e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—NCOR1—hematologic cancer	3.62e-06	7.24e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—GSTM1—hematologic cancer	3.62e-06	7.24e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.61e-06	7.22e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CA9—hematologic cancer	3.58e-06	7.16e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ACP5—hematologic cancer	3.58e-06	7.16e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CD44—hematologic cancer	3.57e-06	7.14e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—NQO1—hematologic cancer	3.57e-06	7.14e-05	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—MAPK3—hematologic cancer	3.54e-06	7.08e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—NCOR1—hematologic cancer	3.54e-06	7.08e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—GSTM1—hematologic cancer	3.54e-06	7.08e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NCOR2—hematologic cancer	3.53e-06	7.07e-05	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—EP300—hematologic cancer	3.52e-06	7.05e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.49e-06	6.99e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—NQO1—hematologic cancer	3.48e-06	6.97e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CD44—hematologic cancer	3.48e-06	6.97e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.45e-06	6.9e-05	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—MYC—hematologic cancer	3.44e-06	6.88e-05	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—SRC—hematologic cancer	3.43e-06	6.85e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.38e-06	6.77e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CYCS—hematologic cancer	3.38e-06	6.75e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—IDH1—hematologic cancer	3.37e-06	6.74e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.36e-06	6.73e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	3.35e-06	6.71e-05	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—VEGFA—hematologic cancer	3.34e-06	6.67e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—GSTP1—hematologic cancer	3.33e-06	6.67e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—GSTO1—hematologic cancer	3.33e-06	6.66e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ABCC3—hematologic cancer	3.33e-06	6.66e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—TXN—hematologic cancer	3.33e-06	6.66e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—GSTP1—hematologic cancer	3.31e-06	6.63e-05	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—NRAS—hematologic cancer	3.3e-06	6.59e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CYCS—hematologic cancer	3.29e-06	6.59e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CD44—hematologic cancer	3.28e-06	6.56e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—NQO1—hematologic cancer	3.28e-06	6.56e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—HSP90AA1—hematologic cancer	3.27e-06	6.55e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—SPHK1—hematologic cancer	3.26e-06	6.52e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CD44—hematologic cancer	3.25e-06	6.51e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—NQO1—hematologic cancer	3.25e-06	6.51e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.23e-06	6.45e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.21e-06	6.42e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—MTHFR—hematologic cancer	3.2e-06	6.4e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.19e-06	6.37e-05	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—MAPK3—hematologic cancer	3.16e-06	6.31e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—ABCB1—hematologic cancer	3.16e-06	6.31e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—ABCB1—hematologic cancer	3.14e-06	6.28e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—UGT1A1—hematologic cancer	3.13e-06	6.26e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—MTHFR—hematologic cancer	3.13e-06	6.25e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CYCS—hematologic cancer	3.1e-06	6.21e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	3.09e-06	6.17e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CYCS—hematologic cancer	3.08e-06	6.16e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—GSTM1—hematologic cancer	3.06e-06	6.13e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—NCOR1—hematologic cancer	3.06e-06	6.13e-05	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—TGFB1—hematologic cancer	3.06e-06	6.13e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	3.06e-06	6.12e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—GSTM1—hematologic cancer	3.05e-06	6.09e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—NCOR1—hematologic cancer	3.05e-06	6.09e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CRABP1—hematologic cancer	3.05e-06	6.09e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—SLC22A1—hematologic cancer	3.05e-06	6.09e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.02e-06	6.04e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—GSTP1—hematologic cancer	2.98e-06	5.95e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ALOX5—hematologic cancer	2.97e-06	5.94e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—GSTP1—hematologic cancer	2.9e-06	5.81e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.88e-06	5.76e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NUP98—hematologic cancer	2.87e-06	5.75e-05	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—KRAS—hematologic cancer	2.84e-06	5.67e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—ABCB1—hematologic cancer	2.82e-06	5.64e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ADCY7—hematologic cancer	2.79e-06	5.58e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NCOA3—hematologic cancer	2.79e-06	5.58e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NUP214—hematologic cancer	2.77e-06	5.54e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.75e-06	5.51e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—GSTP1—hematologic cancer	2.74e-06	5.48e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—NCOR1—hematologic cancer	2.73e-06	5.47e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—GSTM1—hematologic cancer	2.73e-06	5.47e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—MTR—hematologic cancer	2.71e-06	5.43e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.71e-06	5.43e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—GSTP1—hematologic cancer	2.71e-06	5.43e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—MTHFR—hematologic cancer	2.71e-06	5.42e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—MTHFR—hematologic cancer	2.69e-06	5.39e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PIK3CG—hematologic cancer	2.69e-06	5.38e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—NCOR1—hematologic cancer	2.67e-06	5.34e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—GSTM1—hematologic cancer	2.67e-06	5.34e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ENO2—hematologic cancer	2.66e-06	5.32e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PIK3CG—hematologic cancer	2.63e-06	5.25e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.62e-06	5.25e-05	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—PIK3CA—hematologic cancer	2.61e-06	5.21e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—ABCB1—hematologic cancer	2.59e-06	5.18e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.58e-06	5.16e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—ABCB1—hematologic cancer	2.57e-06	5.14e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—SDC1—hematologic cancer	2.52e-06	5.05e-05	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—TP53—hematologic cancer	2.52e-06	5.04e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.52e-06	5.03e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.52e-06	5.03e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—NCOR1—hematologic cancer	2.49e-06	4.99e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—GSTM1—hematologic cancer	2.49e-06	4.99e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—CREBBP—hematologic cancer	2.49e-06	4.98e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—CREBBP—hematologic cancer	2.43e-06	4.87e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—MTHFR—hematologic cancer	2.42e-06	4.83e-05	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—HRAS—hematologic cancer	2.41e-06	4.82e-05	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—AKT1—hematologic cancer	2.39e-06	4.77e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.39e-06	4.77e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.37e-06	4.75e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PIK3CD—hematologic cancer	2.36e-06	4.73e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—MTHFR—hematologic cancer	2.36e-06	4.72e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—ALB—hematologic cancer	2.33e-06	4.66e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PIK3CD—hematologic cancer	2.31e-06	4.62e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—ALB—hematologic cancer	2.28e-06	4.56e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PIK3CG—hematologic cancer	2.27e-06	4.55e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PIK3CG—hematologic cancer	2.26e-06	4.52e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PIK3R1—hematologic cancer	2.23e-06	4.46e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—MTHFR—hematologic cancer	2.22e-06	4.45e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—MTHFR—hematologic cancer	2.2e-06	4.41e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PIK3R1—hematologic cancer	2.18e-06	4.36e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CD44—hematologic cancer	2.15e-06	4.29e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NQO1—hematologic cancer	2.15e-06	4.29e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.13e-06	4.26e-05	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—AKT1—hematologic cancer	2.13e-06	4.26e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CREBBP—hematologic cancer	2.11e-06	4.22e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CREBBP—hematologic cancer	2.1e-06	4.2e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PIK3CB—hematologic cancer	2.06e-06	4.12e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PIK3CG—hematologic cancer	2.03e-06	4.06e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CYCS—hematologic cancer	2.03e-06	4.06e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	2.02e-06	4.04e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PIK3CB—hematologic cancer	2.01e-06	4.03e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PIK3CD—hematologic cancer	2e-06	4e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PIK3CD—hematologic cancer	1.99e-06	3.98e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.98e-06	3.96e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—ALB—hematologic cancer	1.97e-06	3.95e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.94e-06	3.88e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PIK3R1—hematologic cancer	1.89e-06	3.78e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.88e-06	3.77e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PIK3R1—hematologic cancer	1.88e-06	3.76e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.87e-06	3.74e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.85e-06	3.7e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CREBBP—hematologic cancer	1.84e-06	3.68e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.79e-06	3.58e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PIK3CD—hematologic cancer	1.78e-06	3.57e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PTEN—hematologic cancer	1.78e-06	3.56e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—ALB—hematologic cancer	1.76e-06	3.53e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PIK3CB—hematologic cancer	1.74e-06	3.49e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.74e-06	3.49e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PTEN—hematologic cancer	1.74e-06	3.48e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PIK3CB—hematologic cancer	1.73e-06	3.47e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.73e-06	3.46e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—ALB—hematologic cancer	1.72e-06	3.44e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.72e-06	3.43e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—EP300—hematologic cancer	1.7e-06	3.39e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.69e-06	3.39e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.69e-06	3.37e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—EP300—hematologic cancer	1.66e-06	3.32e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.65e-06	3.29e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.64e-06	3.29e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.64e-06	3.29e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.64e-06	3.28e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.63e-06	3.26e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—ALB—hematologic cancer	1.62e-06	3.24e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—ALB—hematologic cancer	1.61e-06	3.21e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.56e-06	3.11e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.55e-06	3.1e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.54e-06	3.07e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.52e-06	3.04e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PTEN—hematologic cancer	1.51e-06	3.01e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PTEN—hematologic cancer	1.5e-06	3e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.45e-06	2.91e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—EP300—hematologic cancer	1.44e-06	2.87e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.43e-06	2.86e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—EP300—hematologic cancer	1.43e-06	2.86e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.42e-06	2.84e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PTEN—hematologic cancer	1.34e-06	2.69e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PTEN—hematologic cancer	1.31e-06	2.63e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—EP300—hematologic cancer	1.28e-06	2.56e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PIK3CA—hematologic cancer	1.26e-06	2.51e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—EP300—hematologic cancer	1.25e-06	2.5e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PTEN—hematologic cancer	1.24e-06	2.47e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PIK3CA—hematologic cancer	1.23e-06	2.45e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PTEN—hematologic cancer	1.23e-06	2.45e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.22e-06	2.44e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—EP300—hematologic cancer	1.18e-06	2.36e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—EP300—hematologic cancer	1.17e-06	2.34e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.13e-06	2.26e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.07e-06	2.15e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PIK3CA—hematologic cancer	1.06e-06	2.13e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ALB—hematologic cancer	1.06e-06	2.12e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PIK3CA—hematologic cancer	1.06e-06	2.11e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—AKT1—hematologic cancer	1.03e-06	2.05e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.01e-06	2.03e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—AKT1—hematologic cancer	1e-06	2e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PIK3CA—hematologic cancer	9.48e-07	1.9e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PIK3CB—hematologic cancer	9.36e-07	1.87e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PIK3CA—hematologic cancer	9.26e-07	1.85e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PIK3CA—hematologic cancer	8.72e-07	1.75e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—AKT1—hematologic cancer	8.68e-07	1.74e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PIK3CA—hematologic cancer	8.65e-07	1.73e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—AKT1—hematologic cancer	8.63e-07	1.73e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PTEN—hematologic cancer	8.08e-07	1.62e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—AKT1—hematologic cancer	7.75e-07	1.55e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—EP300—hematologic cancer	7.71e-07	1.54e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—AKT1—hematologic cancer	7.56e-07	1.51e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—AKT1—hematologic cancer	7.13e-07	1.43e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—AKT1—hematologic cancer	7.06e-07	1.41e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PIK3CA—hematologic cancer	5.7e-07	1.14e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—AKT1—hematologic cancer	4.66e-07	9.32e-06	CbGpPWpGaD
